Efficacy of beta-lactam/beta-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients (INCREMENT-SOT Project)

Creative Commons License

Pierrotti L. C., Perez-Nadales E., Fernandez-Ruiz M., Gutierrez-Gutierrez B., Hock Tan B., Carratala J., ...More

TRANSPLANT INFECTIOUS DISEASE, vol.23, no.3, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 23 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1111/tid.13520
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Keywords: bloodstream infection, carbapenem&#8208, sparing regimen, extended&#8208, spectrum &#946, &#8208, lactamase&#8208, producing Enterobacterales, kidney transplantation, outcomes, urinary tract infection, BLOOD-STREAM INFECTIONS, PIPERACILLIN-TAZOBACTAM, RISK-FACTORS, ESCHERICHIA-COLI, PNEUMONIAE, MORTALITY, EPIDEMIOLOGY, CARBAPENEMS, RESISTANCE, THERAPY
  • Akdeniz University Affiliated: Yes


Background Whether active therapy with beta-lactam/beta-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary to urinary tract infection (UTI) in kidney transplant recipients (KTRs) remains unclear.